anasthetic was to replace ether, the anesthetic would have to be not only non-explosive, but equally safe. This is a very severe requirement.
It is against this background that the Pharmaceutical Division of I.C.I. introduced halothane. They knew that hydrocarbons became less inflammable when fluorine was introduced into the molecule, and they tested a series of compounds containing fluorine, and found that halothane was a satisfactory anmsthetic. According to his description of the pharmacological work, Raventos (1956) began by testing on mice.
Tests on mice.-We have had some experience at Oxford in carrying out tests on mice. Mr. P. J. Goodford has made the experiments under the supervision of Dr. H. G. Epstein. We have -used an apparatus almost identical with that described by Raventos, and found it quite satisfactory. The problem is not merely to find out whether the substance under investigation FEBRUARY will anesthetize mice, but to determine what anmsthetic action is possessed by different concentrations of the substance. Raventos's apparatus was arranged to deliver a known amount of antsthetic per minute into a warm chamber where it met a current of air flowing at a known rate per minute. In the chamber the anmsthetic was vaporized, and thus a current of air containing a known percentage of anesthetic was obtained. The current passed into another larger chamber in which a group of 10 or 15 mice were placed. The effect on the mice was determined during a period which might be 15 or might be 60 minutes. The proportion of mice was observed which were sufficiently anxsthetized (a) to be unable to right themselves, and (b) to be unaffected by a pinch applied at the base of the tail. After exposure to the anesthetic the mice were taken from the chamber and observed during the following two weeks to see if any of them died. Causes of a hypotensive action.-It may be of interest to consider briefly the causes of a hypotensive action in the light of experience with halothane. The blood pressure is maintained by the combined action of the heart and blood vessels, and it is therefore clear that a fall of blood pressure may be caused by weakening of the heart or by loss of tone in the vessels.
The effect of an anesthetic on the output of the heart can be accurately determined in the heart-lung preparation since the venous pressure and venous inflow are kept constant and the arterial pressure is also kept constant. Actually halothane was found -to have a depressant action nearly as great as that of chloroform. However, in the body various compensatory mechanisms are at work and an agent which diminishes the output in the heart-lung preparation may not always diminish the output in man. Finally a fall of blood pressure may be due to the direct action of the anesthetic on the blood vessel walls. Dr. Epstein and I have recently observed that halothane has such an effect on the vessels of the dog's hindleg perfused with blood. The blood was oxygenated by pumping through the lungs, and halothane was administered by mixing it with the air used to inflate the lungs. Halothane in 1-5 % concentration caused a fall in arterial resistance in the leg vessels from 170 to 132 mm. Hg in one trial, and from 153 to 119 mm. Hg in a second. This fall was accompanied by an increased venous outflow, and when halothane was stopped the arterial resistance once more rose. Ether in 6% concentration had no effect of this kind, and in 8 % concentration caused a fall of a few millimetres only.
A new anesthetic should also be tested to see if it makes the heart sensitive to the action of adrenaline when injected intravenously. It is well known that, under chloroform anesthesia, adrenaline administered in this way may cause ventricular fibrillation, and both halothane and cyclopropane have a similar effect. It is important to make certain that a new anaesthetic has no excessive sensitizing action of this kind.
The foregoing observations thus briefly indicate how the action of an anesthetic on the cardiovascular system can be analysed. Such an analysis obviously depends on the use of experimental methods in a pharmacological laboratory. The questions to be asked are these:
(1) What tests must I require to be made, on animals, before I try a new drug on humans?
(2) To what extent may species differences invalidate these tests?
(3) What risk is there that harm will befall the patient in spite of the best that I can do in screening?
In trying to define what is ethical, it is easy to draw up a code so strict that no experimentation at all would be permissible. That would reduce human pharmacology and therapeutics to a theoretical science. At the other extreme is the attitude which can be expressed like this: "in the anwsthetic room and the operating room we have unrivalled opportunities for the practice of applied pharmacology in the human. Let us exploit them to the full." Obviously, the correct attitude lies between these two extremes, and most anesthetists would put it nearer to the first than to the second. Hence, before human experimentation is permissible with new compounds screening in animals must be as thorough as we can make it.
What is this screening expected to do? First, clearly, to enable us to reject compounds which are toxic to the animals used, and hence to homo sapiens. But of course all drugs that are active are "toxic" if we give enough. So we have to define more closely what we mean by toxic; and to do this we make use of the therapeutic ratio, the ratio of the effective dose to the lethal dose, to which Professor Burn has already
